FS222 First in Human Study in Patients With Advanced Malignancies
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 177
- Registration Number
- NCT04740424
- Locations
- 🇪🇸
Instituto de Investigación Sanitaria Fundación Jimenez DÃaz, Madrid, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇪🇸NEXT - Hospital Universitario Quironsalud Madrid, Madrid, Spain
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 82
- Registration Number
- NCT04648202
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 61
- Registration Number
- NCT04096638
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 80
- Registration Number
- NCT03440437
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇫🇷CHU Bordeaux, Bordeaux, France
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath